Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database-Reference-Cited by-同舟云学术

Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database

Published:2022-08 Issue: Volume:119 Page:106903
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Rippel Noa,Tremblay Douglas,Zubizarreta Nicole,Podoltsev Nikolai,Gotlib Jason,Heaney Mark,Kuykendall Andrew,O’Connell Casey,Shammo Jamile M.,Fleischman Angela,Kremyanskaya Marina,Hoffman Ronald,Mesa Ruben,Yacoub Abdulraheem,Mascarenhas John

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study;Gisslinger;Lancet Haematol.,2020

2. Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

3. Oral idasanutlin in patients with polycythemia vera;Mascarenhas;Blood,2019

4. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?;Vannucchi;Hematol. Am. Soc. Hematol. Educ. Program,2017

5. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018;Mesa;J. Natl. Compr. Canc Netw.,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polycythemia Vera Presenting As Acute Non-hemorrhagic Infarction and Chronic Bleed: Deception Between the Lines;Cureus;2024-05-30